Tokushima University / Educator and Researcher Directory --- Nakajima, Kohhei

Field of Study

Subject of Study

Book / Paper

Book:

1.	Sumiko Yoshida, 原倫世, 山口佑樹, Takeshi Kondo, 遠藤ふうり, 筒井康継, 桝田志保, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, Kohhei Nakajima and Masahiro Abe : 急速に腫瘍が増大し悪性転化が疑われたCushing病の1例, Jun. 2019.
2.	Kagusa Hiroshi, Yoshifumi Mizobuchi, Kohhei Nakajima, Koji Fujita, Takashi Abe, Teruyoshi Kageji, Junichiro Satomi, Shinji Nagahiro and Nobuaki Yamamoto : 眼科内腫瘍性病変, Jul. 2015.
3.	Kohhei Nakajima : ブレインナーシング, Medicus SHUPPAN, Tokyo, Dec. 2014.
4.	Kohhei Nakajima and Shinji Nagahiro : 脳神経外科周術期管理のすべて意識障害・脳ヘルニア，脳死, Medicus SHUPPAN, Tokyo, Mar. 2014.

Academic Paper (Judged Full Paper):

1.	Mai Azumi, Yoshifumi Mizobuchi, Nobuto Nakanishi, Kohhei Nakajima, Keijiro Hara, Toshitaka Fujihara, Manabu Ishihara, Jun Oto and Yasushi Takagi : Value of the Acute Physiology and Chronic Health Evaluation II (APACHE II) score in predicting hospital mortality for postoperative brain tumor patients in intensive care units in Japan: A retrospective case-control study, Clinical Neurology and Neurosurgery, Vol.244(2024), No.108435, 108435, 2024. (Summary) Acute Physiology and Chronic Health Evaluation II (APACHE II) is based on the data of intensive care unit (ICU) patients and often correlates with disease severity and prognosis. However, no prognostic predictors exist based on ICU admission data for patients with brain tumors, and no studies have reported an association between APACHE II and prognosis in patients with brain tumors. The Japanese Intensive Care Patients Database (JIPAD) was established to improve the quality of care delivered in intensive care medicine in Japan. We used JIPAD to examine factors associated with in-hospital mortality based on available data of postoperative patients with brain tumors admitted to the ICU. Patients aged ≥16 years enrolled in JIPAD between April 2015 and March 2018 after surgical brain tumor resection or biopsy of brain tumors. We examined factors related to outcomes at discharge based on blood tests and medical procedures performed during ICU admission, tumor type, and APACHE II score. Among the 1454 patients (male:female ratio: 1:1.1, mean age: 62 years) in the study, 32 (2.2 %) died during hospital stay. In multivariate analysis, male sex (odds ratio [OR] 2.70, [95 % confidence interval, CI 1.22-6.00]), malignant tumor (OR 2.51 [95 % CI 1.13-5.55]), and APACHE II score ≥15 (OR 2.51 [95 % CI 3.08-14.3]) were significantly associated with in-hospital mortality. By picking up cases with a high risk of in-hospital death at an early stage, it is possible to improve methods of treatment and support for the patient's family. (Keyword) Humans / Male / Female / Middle Aged / Hospital Mortality / APACHE / Japan / Brain Neoplasms / Aged / Intensive Care Units / Retrospective Studies / Case-Control Studies / Adult / Prognosis / Aged, 80 and over / Predictive Value of Tests (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clineuro.2024.108435 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38996799 ● Summary page in Scopus @ Elsevier: 2-s2.0-85198060266 (DOI: 10.1016/j.clineuro.2024.108435, PubMed: 38996799, Elsevier: Scopus)
2.	Shinji Nagahiro, Yoshifumi Mizobuchi, Kohhei Nakajima and Yasushi Takagi : A Novel Approach to Microvascular Decompression for Hemifacial Spasm: Method Description and Associated Outcome, Operative Neurosurgery, Vol.00, 1-7, 2022. (Summary) Microvascular decompression (MVD) is the only potential cure for hemifacial spasm (HFS). However, traditional techniques such as the interposition method may have limited effect in some cases. Alternative techniques have been proposed; however, they can be more complex or difficult to perform than the standard approach. To describe a safe decompression technique-the "shelter method"-which involves creating a shelter-like space around the facial nerve root exit zone and present associated outcomes. Medical records and intraoperative findings of 92 patients with HFS who underwent MVD using the shelter method between April 1997 and March 2017 were retrospectively reviewed. As a historical control group, we included 53 patients who had undergone MVD by the traditional interposition method before March 1989. The patients were divided into 3 subgroups according to the arteries involved and degree or direction of arterial compression to the seventh nerve. Patient outcomes were assessed as excellent, good, fair, and poor according to the MVD scoring system of the Japan Society for MVD Surgery. In the shelter method group, complete disappearance of HFS was achieved in 87 patients (94.6%). The curative rate of the shelter method group was significantly higher than that of the interposition method group. The overall complication rates were significantly lower in the shelter method group than in the interposition method group. Our findings indicate high curative and low complication rates of the shelter method, suggesting that it helps treat HFS caused by various types of arterial compression. (Keyword) Facial Nerve / Hemifacial Spasm / Humans / Microvascular Decompression Surgery / Retrospective Studies / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1227/ons.0000000000000223 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35486878 ● Search Scopus @ Elsevier (PMID): 35486878 ● Search Scopus @ Elsevier (DOI): 10.1227/ons.0000000000000223 (DOI: 10.1227/ons.0000000000000223, PubMed: 35486878)
3.	Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Mai Azumi and Yasushi Takagi : Development of a Navigation-guided Fence-post Catheter for Brain Tumor Resection, The Journal of Medical Investigation : JMI, Vol.69, No.1,2, 117-119, 2022. (Summary) Navigation system devices have been developed to allow precise resection of brain tumor. The fence-post catheter techniques that use a navigation system have been used in many neurosurgery centers. However, an exclusive catheter for the fence-post catheter techniques have not been made, and substituted silicon tube of the cerebral ventricle drainage or a Nelaton catheter is widely used. In this brief technical note, we describe a new fence-post catheter with steel tip device that was designed for more precise tissue resection and is useful in tumor resection. The newly designed fence-post catheter helps to visually gauge the accurate depth from the tumor bottom during tumor resection. Furthermore, the catheter tip has moderate weight and is made of a non-magnetic material. Using our fence-post catheter, which has a metal part at the tip of the tube (length, 13 mm), operators can clearly notice that they are getting closer to base of the tumor by checking the metal part during the resection of deep tumors. Our newly developed fence-post tube enables easy confirmation of the distance to deep-tissue regions and improves the degree of safety during tumor removal. J. Med. Invest. 69 : 117-119, February, 2022. (Keyword) Brain / Brain Neoplasms / Catheters / Glioma / Humans / Neurosurgical Procedures (Tokushima University Institutional Repository) ● Metadata: 117022 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.117 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466132 ● Summary page in Scopus @ Elsevier: 2-s2.0-85128801353 (Tokushima University Institutional Repository: 117022, DOI: 10.2152/jmi.69.117, PubMed: 35466132, Elsevier: Scopus)
4.	Kenji Shono, Yoshifumi Mizobuchi, Izumi Yamaguchi, Kohhei Nakajima, Yuri Fujiwara, Toshitaka Fujihara, Keiko Kitazato, Kazuhito Matsuzaki, Yoshihiro Uto, Oltea Sampetrean, Hideyuki Saya and Yasushi Takagi : Elevated cellular PpIX potentiates sonodynamic therapy in a mouse glioma stem cell-bearing glioma model by downregulating the Akt/NF-κB/MDR1 pathway., Scientific Reports, Vol.11, No.1, 2021. (Summary) Glioblastoma (GBM) has high mortality rates because of extreme therapeutic resistance. During surgical resection for GBM, 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PpIX) fluorescence is conventionally applied to distinguish GBM. However, surgical intervention is insufficient for high invasive GBM. Sonodynamic therapy (SDT) combined with low-intensity ultrasonication (US) and PpIX, as a sonosensitizer, is an emerging and promising approach, although its efficacy is limited. Based on our previous study that down-regulation of multidrug resistant protein (MDR1) in GBM augmented the anti-tumor effects of chemotherapy, we hypothesized that elevation of cellular PpIX levels by down-regulation of MDR1 enhances anti-tumor effects by SDT. In high invasive progeny cells from mouse glioma stem cells (GSCs) and a GSC-bearing mouse glioma model, we assessed the anti-tumor effects of SDT with a COX-2 inhibitor, celecoxib. Down-regulation of MDR1 by celecoxib increased cellular PpIX levels, as well as valspodar, an MDR1 inhibitor, and augmented anti-tumor effects of SDT. MDR1 down-regulation via the Akt/NF-κB pathway by celecoxib was confirmed, using an NF-κB inhibitor, CAPÉ. Thus, elevation of cellar PpIX by down-regulation of MDR1 via the Akt/NF-κB pathway may be crucial to potentiate the efficacy of SDT in a site-directed manner and provide a promising new therapeutic strategy for GBM. (Keyword) ATP Binding Cassette Transporter, Subfamily B, Member 1 / Aminolevulinic Acid / Animals / Cell Line, Tumor / Down-Regulation / Glioblastoma / Glioma / Male / Mice / Mice, Inbred C57BL / NF-kappa B / Neoplastic Stem Cells / Photosensitizing Agents / Proto-Oncogene Proteins c-akt / Protoporphyrins / Signal Transduction / Ultrasonic Therapy (Tokushima University Institutional Repository) ● Metadata: 116448 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-021-93896-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34301977 ● Search Scopus @ Elsevier (PMID): 34301977 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-021-93896-0 (Tokushima University Institutional Repository: 116448, DOI: 10.1038/s41598-021-93896-0, PubMed: 34301977)
5.	Kenji Shimada, Yoko Yamamoto, Takeshi Miyamoto, Shu Sogabe, Toshitaka Fujihara, Kohhei Nakajima, Yoshifumi Mizobuchi, Yasuhisa Kanematsu and Yasushi Takagi : Efficacy of Intra-arterial Indocyanine Green Videoangiography in Hemangioblastoma Surgery: A Case Report., NMC Case Report Journal, Vol.8, No.1, 295-300, 2021. (Summary) Intravenous indocyanine green (ICG) videoangiography is reportedly useful for vascular neurosurgery, and for treating hemangioblastoma due to its high vascularity. Videoangiography obtained after intra-arterial ICG injection has emerged as a more useful option than that after intravenous injection. This report offers the first description of a case of hemangioblastoma successfully treated using intra-arterial ICG videoangiography, and describes the efficacy of this technique. A 20-year-old man presented with progressive cerebellar ataxia and dysphagia. Magnetic resonance imaging (MRI) revealed an enhanced solid tumor in the medulla oblongata. Digital subtraction angiography (DSA) showed a highly vascularized tumor. Surgery was performed to remove the tumor in a hybrid operating room. A catheter was introduced into the vertebral artery (VA) for intra-arterial ICG videoangiography. Superficial feeders and drainers were identified and flow dynamic changes in the tumor were assessed by intra-arterial ICG videoangiography. The tumor was removed after confirming lack of flow in the drainer. Intra-arterial ICG videoangiography was more useful than intravenous ICG videoangiography in hemangioblastoma surgery for identifying feeders and drainers and assessing flow dynamics in the tumor. Use of Flow 800 made these findings simpler and easier to evaluate. (Link to Publication Site) ● Publication site (DOI): 10.2176/nmccrj.cr.2020-0281 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35079478 ● Search Scopus @ Elsevier (PMID): 35079478 ● Search Scopus @ Elsevier (DOI): 10.2176/nmccrj.cr.2020-0281 (DOI: 10.2176/nmccrj.cr.2020-0281, PubMed: 35079478)
6.	Yoshifumi Mizobuchi, Aki Shimada, Kohhei Nakajima, Hiroshi Kagusa and Yasushi Takagi : Reversible Hearing Impairment Due to Inferior Colliculi Compression by a Pineal Glial Cyst, NMC Case Report Journal, Vol.8, No.1, 79-84, 2021. (Link to Publication Site) ● Publication site (DOI): 10.2176/nmccrj.cr.2020-0123 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34012754 ● CiNii @ National Institute of Informatics (CRID): 1390850247501001984 ● Search Scopus @ Elsevier (PMID): 34012754 ● Search Scopus @ Elsevier (DOI): 10.2176/nmccrj.cr.2020-0123 (DOI: 10.2176/nmccrj.cr.2020-0123, PubMed: 34012754, CiNii: 1390850247501001984)
7.	Kohhei Nakajima, Yoshifumi Mizobuchi, Toshitaka Fujihara, Mai Azumi and Yasushi Takagi : Continued-Maintenance Therapy with High-dose Methotrexate Improves Overall Survival of Patients with Primary Central Nervous System Lymphoma., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 286-291, 2021. (Summary) In 3-year overall survival (OS) there was a statistically significant difference between the two groups [controls : 33.1% (95%, CI 12.4 - 55.7%) ; maintenance group : 74.9% (95%, CI 55.6 - 86.7%) (p < 0.02)]. Conclusion : The induction of HD-MTX based chemotherapy followed by continued-maintenance HD-MTX monotherapy improved OS compared with chemoradiotherapy consisting of HD-MTX followed by WBRT. J. Med. Invest. 68 : 286-291, August, 2021. (Keyword) Aged / Antineoplastic Combined Chemotherapy Protocols / Central Nervous System / Central Nervous System Neoplasms / Humans / Lymphoma, Non-Hodgkin / Methotrexate / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116496 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.286 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759146 ● Search Scopus @ Elsevier (PMID): 34759146 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.286 (Tokushima University Institutional Repository: 116496, DOI: 10.2152/jmi.68.286, PubMed: 34759146)
8.	Izumi Yamaguchi, Yasuhisa Kanematsu, Kenji Shimada, Kohhei Nakajima, Takeshi Miyamoto, Shu Sogabe, Eiji Shikata, Manabu Ishihara, Mai Azumi, Ayato Kageyama and Yasushi Takagi : Gelatinthrombin Hemostatic Matrix-related Cyst Formation after Cerebral Hematoma Evacuation: A Report of Two Cases, NMC Case Report Journal, Vol.8, No.1, 719-725, 2021. (Link to Publication Site) ● Publication site (DOI): 10.2176/nmccrj.cr.2021-0130 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2176/nmccrj.cr.2021-0130 (DOI: 10.2176/nmccrj.cr.2021-0130)
9.	Kenji Shono, Izumi Yamaguchi, Yoshifumi Mizobuchi, Hiroshi Kagusa, Akiko Sumi, Toshitaka Fujihara, Kohhei Nakajima, T Keiko Kitazato, Kazuhito Matsuzaki, Hideyuki Saya and Yasushi Takagi : Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma., Scientific Reports, Vol.10, No.1, 2020. (Summary) microglia. In GSCs, celecoxib inhibited Ccl2 and Cxcr3 expression in a nuclear factor-kappa B-dependent manner but not Ccr2 and CxcL10. Moreover, Ccl2 silencing resulted in decreased GSC viability. These results suggest that celecoxib-mediated regulation of the CCL2/CCR2 and CXCL10/ CXCR3 axes may partially contribute to glioma-specific antitumor effects. (Keyword) Animals / Antineoplastic Agents / Cell Line / Chemokine CCL2 / Chemokine CXCL10 / Disease Models, Animal / Down-Regulation / Glioma / Humans / Male / Mice / Mice, Inbred C57BL / Microglia / Receptors, CCR2 / Receptors, CXCR3 / Stem Cells / Tumor Microenvironment (Tokushima University Institutional Repository) ● Metadata: 117722 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-020-71857-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32943658 ● Search Scopus @ Elsevier (PMID): 32943658 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-020-71857-3 (Tokushima University Institutional Repository: 117722, DOI: 10.1038/s41598-020-71857-3, PubMed: 32943658)
10.	Hiroshi Kagusa, Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Yoshimi Bando and Yasushi Takagi : Metastatic tumor to the orbital cavity from a primary carcinoma of the uterine cervix : a case report., The Journal of Medical Investigation : JMI, Vol.66, No.3,4, 355-357, 2019. (Summary) Metastatic tumors to the orbit of the eye, especially from primary carcinomas of the uterine cervix are very rare. A 64-year-old woman with a history of carcinoma of the uterine cervix presented with right eye pain and blepharoptosis for 2 weeks. Magnetic resonance imaging revealed a mass at the right orbital apex. Surgical extirpation was performed due to severe pain. Postoperative pathology demonstrated a poorly differentiated squamous cell carcinoma. The origin was ultimately considered to be the carcinoma of the uterine cervix. In conclusion, this report describes a rare case of a metastatic tumor at the orbital apex derived from the cervix of the uterus. J. Med. Invest. 66 : 355-357, August, 2019. (Tokushima University Institutional Repository) ● Metadata: 114169 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.355 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656305 ● Search Scopus @ Elsevier (PMID): 31656305 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.355 (Tokushima University Institutional Repository: 114169, DOI: 10.2152/jmi.66.355, PubMed: 31656305)
11.	Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Kazuhito Matsuzaki, Hideo Mure, Shinji Nagahiro and Yasushi Takagi : The risk of hemorrhage in stereotactic biopsy for brain tumors., The Journal of Medical Investigation : JMI, Vol.66, No.3,4, 314-318, 2019. (Summary) Objective : One major complication associated with STB is intratumoral hematoma, which is also the most common cause of morbidity related to permanent paralysis and mortality in STB. The risk of perioperative hemorrhage is generally between 1% and 10%, but this could be an underestimation since it is not common for many neurosurgeons to perform CT scans after uncomplicated STBs. In this study, we describe the incidence of cerebral hemorrhage, including asymptomatic cerebral hemorrhage. Methods : We recently reviewed data on the diagnosis rate and occurrence of complications, including symptomatic and asymptomatic cerebral hemorrhage, in 80 patients who underwent STB at our facility between 2005 and 2014. Results : Histological diagnosis was established for 75 cases (93.8%), glioma was the most frequently encountered tumor. Symptomatic hemorrhage was observed in two cases (2.6%), with the symptoms subsiding within two days. The morbidity and mortality rate was 0%. However, asymptomatic hemorrhages were observed in 23 cases (28.8%). Conclusion : Stereotactic biopsy is a less invasive procedure for obtaining samples of brain tumors for diagnosis. The bleeding of the tissue-resection cavity that includes asymptomatic hemorrhage occurs at a constant rate. It is important to reduce the symptomatic bleeding associated with stereotactic biopsy. J. Med. Invest. 66 : 314-318, August, 2019. (Keyword) Adolescent / Adult / Aged / Aged, 80 and over / Biopsy / Brain / Brain Neoplasms / Cerebral Hemorrhage / Female / Humans / Male / Middle Aged / Stereotaxic Techniques / Young Adult (Tokushima University Institutional Repository) ● Metadata: 114088 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.314 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656296 ● Search Scopus @ Elsevier (PMID): 31656296 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.314 (Tokushima University Institutional Repository: 114088, DOI: 10.2152/jmi.66.314, PubMed: 31656296)
12.	Shinji Nagahiro, Yoshiteru Tada, Junichiro Satomi, Tomoya Kinouchi, Kazuyuki Kuwayama, Kenji Yagi, Kohhei Nakajima, Nobuhisa Matsushita, Takeshi Miyamoto, Tadashi Yamaguchi, Kenji Shimada, Masaaki Korai, Hideo Mure, Y Okayama, Takashi Abe, Masafumi Harada, Keiko T. Kitazato and Yasuhisa Kanematsu : Treatment of Unruptured Cerebral Aneurysms with the Mineralocorticoid Receptor Blocker Eplerenone-Pilot Study., Journal of Stroke & Cerebrovascular Diseases, Vol.27, No.8, 2134-2140, 2018. (Summary) Currently there are no pharmacological therapies for patients with unruptured cerebral aneurysms. Elsewhere we showed that the mineralocorticoid receptor antagonist eplerenone prevented the formation of cerebral aneurysms in our ovariectomized hypertensive aneurysm rat model. The current pilot study evaluated whether it can be used to prevent the growth and rupture of cerebral aneurysms in hypertensive patients. Between August 2011 and May 2014, we enrolled 82 patients with 90 aneurysms in an open-label uncontrolled clinical trial. All provided prior informed consent for inclusion in this study, and all were treated with eplerenone (25-100 mg/d). The primary end points of our study were the rupture and enlargement of the cerebral aneurysms. Of the 82 patients, 80 (88 unruptured aneurysms) were followed for a mean of 21.3 months (153.4 aneurysm-years); 12 patients (15.0%) permanently discontinued taking the drug. One month after the start of eplerenone administration and throughout the follow-up period, eplerenone kept the blood pressure within the normal range. Most notably, no aneurysms smaller than 9 mm ruptured or enlarged. However, of 2 large thrombosed aneurysms, 1 enlarged and the other ruptured. The overall annual rupture rate was .65%; it was 13.16% for aneurysms larger than 10 mm; the overall annual rate for reaching the primary end points was 1.30%. Our observations suggest that eplerenone may help to prevent the growth and rupture of unruptured cerebral aneurysms smaller than 9 mm. To assess its potential long-term clinical benefits, large clinical trials are needed. (Keyword) Aged / Aneurysm, Ruptured / brain / Disease Progression / female / Follow-Up Studies / Humans / Intracranial Aneurysm / male / Mineralocorticoid Receptor Antagonists / Neuroprotective Agents / Pilot Projects / Spironolactone / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 115570 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jstrokecerebrovasdis.2018.03.008 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29622372 ● Summary page in Scopus @ Elsevier: 2-s2.0-85049537109 (Tokushima University Institutional Repository: 115570, DOI: 10.1016/j.jstrokecerebrovasdis.2018.03.008, PubMed: 29622372, Elsevier: Scopus)
13.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Teruyoshi Kageji, Kazuhito Matsuzaki, KT Kitazato, Ryotaro Otsuka, Keijiro Hara, Hideo Mure, Toshiyuki Okazaki, Kazuyuki Kuwayama, Shinji Nagahiro and Yasushi Takagi : Down-regulation of MDR1 by Ad-DKK3 via Akt/NFB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model, Journal of Neuro-Oncology, Vol.139, No.2, 323-332, 2018. (Summary) Glioblastoma multiforme (GBM) is the most malignant of brain tumors. Acquired drug resistance is a major obstacle for successful treatment. Earlier studies reported that expression of the multiple drug resistance gene (MDR1) is regulated by YB-1 or NFκB via the JNK/c-Jun or Akt pathway. Over-expression of the Dickkopf (DKK) family member DKK3 by an adenovirus vector carrying DKK3 (Ad-DKK3) exerted anti-tumor effects and led to the activation of the JNK/c-Jun pathway. We investigated whether Ad-DKK3 augments the anti-tumor effect of temozolomide (TMZ) via the regulation of MDR1. GBM cells (U87MG and U251MG), primary TGB105 cells, and mice xenografted with U87MG cells were treated with Ad-DKK3 or TMZ alone or in combination. Ad-DKK3 augmentation of the anti-tumor effects of TMZ was associated with reduced MDR1 expression in both in vivo and in vitro studies. The survival of Ad-DKK3-treated U87MG cells was inhibited and the expression of MDR1 was reduced. This was associated with the inhibition of Akt/NFκB but not of YB-1 via the JNK/c-Jun- or Akt pathway. Our results suggest that Ad-DKK3 regulates the expression of MDR1 via Akt/NFκB pathways and that it augments the anti-tumor effects of TMZ in GBM cells. (Tokushima University Institutional Repository) ● Metadata: 112895 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11060-018-2894-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29779087 ● Summary page in Scopus @ Elsevier: 2-s2.0-85047143200 (Tokushima University Institutional Repository: 112895, DOI: 10.1007/s11060-018-2894-5, PubMed: 29779087, Elsevier: Scopus)
14.	Masanori Niki, Kohhei Nakajima, Daichi Ishikawa, Jun Nishida, Chieko Ishifune, Shin-ichi Tsukumo, Mitsuo Shimada, Shinji Nagahiro, Yoshinori Mitamura and Koji Yasutomo : MicroRNA-449a deficiency promotes colon carcinogenesis., Scientific Reports, Vol.7, No.1, 10696, 2017. (Summary) MicroRNAs have broad roles in tumorigenesis and cell differentiation through regulation of target genes. Notch signaling also controls cell differentiation and tumorigenesis. However, the mechanisms through which Notch mediates microRNA expression are still unclear. In this study, we aimed to identify microRNAs regulated by Notch signaling. Our analysis found that microRNA-449a (miR-449a) was indirectly regulated by Notch signaling. Although miR-449a-deficient mice did not show any Notch-dependent defects in immune cell development, treatment of miR-449a-deficient mice with azoxymethane (AOM) or dextran sodium sulfate (DSS) increased the numbers and sizes of colon tumors. These effects were associated with an increase in intestinal epithelial cell proliferation following AOM/DSS treatment. In patients with colon cancer, miR-449a expression was inversely correlated with disease-free survival and histological scores and was positively correlated with the expression of MLH1 for which loss-of function mutations have been shown to be involved in colon cancer. Colon tissues of miR-449a-deficient mice showed reduced Mlh1 expression compared with those of wild-type mice. Thus, these data suggested that miR-449a acted as a key regulator of colon tumorigenesis by controlling the proliferation of intestinal epithelial cells. Additionally, activation of miR-449a may represent an effective therapeutic strategy and prognostic marker in colon cancer. (Tokushima University Institutional Repository) ● Metadata: 112383 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-017-10500-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28878284 ● Summary page in Scopus @ Elsevier: 2-s2.0-85029002400 (Tokushima University Institutional Repository: 112383, DOI: 10.1038/s41598-017-10500-0, PubMed: 28878284, Elsevier: Scopus)
15.	Kiyoe Kurahashi, Itsuro Endo, Takeshi Kondo, Kana Morimoto, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Kohhei Nakajima, Yoshifumi Mizobuchi, Shinji Nagahiro, Masahiro Abe and Seiji Fukumoto : Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review., Internal Medicine, Vol.56, No.18, 2455-2461, 2017. (Summary) Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case. (Tokushima University Institutional Repository) ● Metadata: 114396 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.8223-16 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28824054 ● Summary page in Scopus @ Elsevier: 2-s2.0-85029653591 (Tokushima University Institutional Repository: 114396, DOI: 10.2169/internalmedicine.8223-16, PubMed: 28824054, Elsevier: Scopus)
16.	Teruyoshi Kageji, Yoshifumi Mizobuchi, Kohhei Nakajima and Shinji Nagahiro : Postoperative Hematoma Requiring Recraniotomy in 1149 Consecutive Patients with Intracranial Tumors, Operative Neurosurgery, Vol.13, No.3, 392-397, 2017. (Summary) The reported 30-day mortality rate after brain tumor surgery is 2.2% to 2.9%, with a postoperative hematoma (POH) as the most frequent cause of death. To investigate the risk factors for a POH requiring a recraniotomy after brain tumor surgery in a large, contemporary, single-institution consecutive series. We included 1149 patients who underwent surgery for intracranial tumors at the Tokushima University Hospital from 1997 to 2014. The patient charts were retrospectively studied from our prospectively collected database. We analyzed the risk factors, type of hemorrhage, time to reoperation, and outcomes. The incidence of a POH requiring a recraniotomy was 2.09%. Among the patients with a POH requiring a recraniotomy, 12.5% died within 30 days of the first surgery. The incidence of a POH requiring a recraniotomy significantly correlated with the incidence of a hemangioblastoma, infratentorial tumors, and a prolonged operative time (>10 h), but not with the patient age or sex, surgical procedure (biopsy or craniotomy), surgical type (primary or secondary), bleeding volume, or intraoperative blood transfusion requirement. A recraniotomy for a POH was performed in 54% of the patients just after the first operation, and within 24 h for 79% of the patients. The clinical status at the time of discharge deteriorated in 52% of the patients. Hemangioblastomas, infratentorial tumors, and an operative time exceeding 10 h were significantly correlated with an increased risk of a POH; these factors were responsible for 12.5% of the 30-day surgical mortality rate. (Link to Publication Site) ● Publication site (DOI): 10.1093/ons/opw045 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28521349 ● Search Scopus @ Elsevier (PMID): 28521349 ● Search Scopus @ Elsevier (DOI): 10.1093/ons/opw045 (DOI: 10.1093/ons/opw045, PubMed: 28521349)
17.	Aya Sato, Yoshifumi Mizobuchi, Kohhei Nakajima, Kenji Shono, Toshitaka Fujihara, Teruyoshi Kageji, Keiko Kitazato, Kazuhito Matsuzaki, Hideo Mure, Kazuyuki Kuwayama, Akiko Sumi, Hideyuki Saya, Oltea Sampetrean and Shinji Nagahiro : Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma., Journal of Neuro-Oncology, Vol.132, No.2, 231-238, 2017. (Summary) Approximately half of surgically-treated patients with low-grade-glioma (LGG) suffer recurrence or metastasis. Currently there is no effective drug treatment. While the selective COX-2 inhibitor celecoxib showed anti-neoplastic activity against several malignant tumors, its effects against LGG remain to be elucidated. Ours is the first report that the expression level of COX-2 in brain tissue samples from patients with LGG and in LGG cell lines is higher than in the non-neoplastic region and in normal brain cells. We found that celecoxib attenuated LGG cell proliferation in a dose-dependent manner. It inhibited the generation of prostaglandin E2 and induced apoptosis and cell-cycle arrest. We also show that celecoxib hampered the activation of the Akt/survivin- and the Akt/ID3 pathway in LGGs. These findings suggest that celecoxib may have a promising therapeutic potential and that the early treatment of LGG patients with the drug may be beneficial. (Keyword) Animals / Apoptosis / Brain / Brain Neoplasms / Celecoxib / Cell Line, Tumor / Cell Proliferation / Cyclooxygenase 2 / Cyclooxygenase 2 Inhibitors / Enzyme Inhibitors / Female / Gene Expression Regulation, Neoplastic / Glioma / Humans / Inhibitor of Apoptosis Proteins / Inhibitor of Differentiation Proteins / Male / Mice / Mice, Inbred C57BL / Mice, Transgenic / Neoplasm Proteins / Proto-Oncogene Proteins c-akt / Signal Transduction (Tokushima University Institutional Repository) ● Metadata: 115523 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11060-017-2380-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28283800 ● Search Scopus @ Elsevier (PMID): 28283800 ● Search Scopus @ Elsevier (DOI): 10.1007/s11060-017-2380-5 (Tokushima University Institutional Repository: 115523, DOI: 10.1007/s11060-017-2380-5, PubMed: 28283800)
18.	Teruyoshi Kageji, Takeshi Miyamoto, Yumiko Kotani, Tuyoshi Kaji, Yoshimi Bando, Yoshifumi Mizobuchi, Kohhei Nakajima and Shinji Nagahiro : Congenital craniopharyngioma treated by radical surgery: case report and review of the literature, Child's Nervous System, Vol.33, No.2, 357-362, 2016. (Summary) Craniopharyngiomas are 5-10 % of all pediatric tumors, but are seldomly encountered in the perinatal period. Only seven instances of a truly antenatal diagnosis of a congenital craniopharyngioma that subsequently underwent radical surgery have been reported. We present the case of a patient who received the diagnosis of a suprasellar tumor during the prenatal period and received radical surgery. We report a case of a neonatal craniopharyngioma treated surgically. The pregnancy progressed uneventfully until a routine ultrasound at 37 weeks of gestation showed a 15 × 15 mm high echoic mass in the center of the fetal head. Neonatal Gd-enhanced T1-weighted MRI at 5 days of life showed a homogenously enhanced mass (16×22×15 mm) in the sellar and suprasellar lesion. As the tumor showed rapid growth at the 3rd month of life, the patient underwent a surgical treatment and the mass was totally removed. Three years later, the physical and mental development of the patient was normal, and Gd-MRI studies showed no tumor recurrence. The present case is the eighth case of a truly antenatal diagnosis of a craniopharyngioma that underwent successful radical surgery. Craniopharyngioma is a benign tumor and thought to be a slow growing tumor in childhood. The results of radical surgery were very poor, and the mortality and morbidity rates were high in the previous reports due to the huge size of tumor at operation. The present case demonstrated the rapid growth in short interval of Gd-MRI. This is the first report of tumor kinetics of congenital craniopharyngioma with previous reports. The calculated tumor doubling time in our case was 37 days. (Keyword) Craniopharyngioma / Female / Humans / magnetic resonance imaging / Neurosurgical Procedures / Pituitary Neoplasms / Pregnancy / Tomography, X-Ray Computed / Ultrasonography, Prenatal (Link to Publication Site) ● Publication site (DOI): 10.1007/s00381-016-3249-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27669698 ● Summary page in Scopus @ Elsevier: 2-s2.0-84991294478 (DOI: 10.1007/s00381-016-3249-1, PubMed: 27669698, Elsevier: Scopus)
19.	Yoshifumi Mizobuchi, Kenji Shono, Kohhei Nakajima and Shinji Nagahiro : Trigeminal neuralgia caused by fibrous bands: case illustration, Journal of Neurosurgery, Vol.124, No.1, 186-187, 2016. (Keyword) Adult / Carcinoma, Squamous Cell / Cerebellar Neoplasms / Cerebellopontine Angle / Constriction, Pathologic / Female / Humans / magnetic resonance imaging / Neurosurgical Procedures / Pain, Intractable / Trigeminal Neuralgia (Link to Publication Site) ● Publication site (DOI): 10.3171/2014.12.JNS1463 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26115469 ● Summary page in Scopus @ Elsevier: 2-s2.0-84966397531 (DOI: 10.3171/2014.12.JNS1463, PubMed: 26115469, Elsevier: Scopus)
20.	平井聡, Teruyoshi Kageji, 庄野健児, Kohhei Nakajima, Yoshifumi Mizobuchi, Shinji Nagahiro and Masaaki Uno : 腰椎ドレナージを併用した開頭術後に続発性脳脊髄液漏出症を合併した1例,, Practical Currently, Vol.26, No.2, 183-190, 2016.
21.	Teruyoshi Kageji, Kenji Shono, Yoshifumi Mizobuchi, Kohhei Nakajima, Shinji Nagahiro and Y Nakagawa : Radiation-induced meningiomas after BNCT in patients with malignant glioma,, Applied Radiation and Isotopes, Vol.106, 256-259, 2015. (Summary) Of the 180 patients with malignant brain tumors whom we treated with boron neutron capture therapy (BNCT) since 1968, only one (0.56%) developed multiple radiation-induced meningiomas. The parasagittal meningioma that had received 42 Gy (w) for BNCT showed more rapid growth on Gd-enhanced MRI scans and more atypical features on histopathologic studies than the temporal convexity tumor that had received 20 Gy (w). Long-term follow up MRI studies are necessary in long-survivors of malignant brain tumors treated by BNCT. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.apradiso.2015.06.004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26122975 ● Search Scopus @ Elsevier (PMID): 26122975 ● Search Scopus @ Elsevier (DOI): 10.1016/j.apradiso.2015.06.004 (DOI: 10.1016/j.apradiso.2015.06.004, PubMed: 26122975)
22.	Takashi Abe, Yoshifumi Mizobuchi, Kohhei Nakajima, Youichi Otomi, Saho Irahara, Yuki Obama, Mungunkhuyag Majigsuren, Delgerdalai Khashbat, Teruyoshi Kageji, Shinji Nagahiro and Masafumi Harada : Diagnosis of brain tumors using dynamic contrast-enhanced perfusion imaging with a short acquisition time, SpringerPlus, Vol.24, No.4, 88, 2015. (Summary) This study sought to determine the diagnostic utility of perfusion parameters derived from dynamic contrast-enhanced (DCE) perfusion MRI with a short acquisition time (approximately 3.5 min) in patients with glioma, brain metastasis, and primary CNS lymphoma (PCNSL). Twenty-six patients with 29 lesions (4 low-grade glioma, 13 high-grade glioma, 7 metastasis, and 5 PCNSL) underwent DCE-MRI in a 3 T scanner. A ROI was placed on the hotspot of each tumor in maps for volume transfer contrast K (trans) , extravascular extracellular volume V e , and fractional plasma volume V p . We analyzed differences in parameters between tumors using the Mann-Whitney U test. We calculated sensitivity and specificity using receiver operating characteristics analysis. Mean K (trans) values of LGG, HGG, metastasis and PCNSL were 0.034, 0.31, 0.38, 0.44, respectively. Mean Ve values of each tumors was 0.036, 0.57, 0.47, 0.96, and mean Vp value of each tumors was 0.070, 0.086, 0.26, 0.17, respectively. Compared with other tumor types, low-grade glioma showed lower K (trans) (P < 0.01, sensitivity = 88%, specificity = 100%) and lower V e (P < 0.01, sensitivity = 96%, specificity = 100%). PCNSL showed higher V e (P < 0.01, sensitivity = 100%, specificity = 88%), but the other perfusion parameters overlapped with those of different histology. Kinetic parameters derived from DCE-MRI with short acquisition time provide useful information for the differential diagnosis of brain tumors. (Tokushima University Institutional Repository) ● Metadata: 109680 (Link to Publication Site) ● Publication site (DOI): 10.1186/s40064-015-0861-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25793147 ● Summary page in Scopus @ Elsevier: 2-s2.0-84924942590 (Tokushima University Institutional Repository: 109680, DOI: 10.1186/s40064-015-0861-6, PubMed: 25793147, Elsevier: Scopus)
23.	Norio Nakajima, Shinji Nagahiro, Junichiro Satomi, Yoshiteru Tada, Kohhei Nakajima, Shu Sogabe, Mami Hanaoka, Shunji Matsubara, Masaaki Uno and Koichi Satoh : Prevention of retrograde blood flow into large or giant internal carotid artery aneurysms by endovascular coil embolization with high-flow bypass: surgical technique and long-term results, World Neurosurgery, Vol.83, No.6, 1127-1134, 2015. (Summary) Recanalization has been reported in large or giant aneurysms of the internal carotid artery (ICA) addressed by high-flow bypass and endovascular treatment. Aneurysmal recanalization may be attributable to retrograde blood flow into the aneurysm through the ICA branches, such as the ophthalmic artery or the meningohypophyseal trunk, or through the surgically created bypass. We modified the endovascular treatment of aneurysms to prevent retrograde flow and evaluated the long-term efficacy of our method. We used a hybrid operative/endovascular technique to treat 5 patients with large or giant aneurysms arising from the C2-C4 segment of the ICA who presented with visual symptoms due to the mass effect of the aneurysm. To prevent retrograde flow into the aneurysm our modified endovascular treatment involves coil embolization of the aneurysmal orifice and the ICA, including the origin of the ophthalmic artery and meningohypophyseal trunk, and placement of a high-flow bypass using a radial artery graft. During the 5- to 12-year follow-up period, 4 aneurysms disappeared, and the other decreased in size. There were no subarachnoid hemorrhages. All bypass grafts remained patent. Visual preservation was achieved in 2 patients; 1 patient manifested visual improvement. Although 2 patients experienced transient neurological deficits we encountered no permanent complications in this series. The final modified Rankin scale of the 5 patients was 0 or 1. Prevention of retrograde flow into the aneurysm by coil embolization with high-flow bypass is a safe and effective method. It prevents the recanalization of large or giant ICA aneurysms. (Keyword) Adult / Aged / Angiography / Blood Flow Velocity / Carotid Artery, Internal, Dissection / Cerebrovascular Circulation / Embolization, Therapeutic / Endovascular Procedures / Female / Follow-Up Studies / Humans / magnetic resonance imaging / Male / Middle Aged / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1016/j.wneu.2015.01.037 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25681599 ● Summary page in Scopus @ Elsevier: 2-s2.0-84930929071 (DOI: 10.1016/j.wneu.2015.01.037, PubMed: 25681599, Elsevier: Scopus)
24.	Keijiro Hara, Teruyoshi Kageji, Yoshifumi Mizobuchi, Keiko T. Kitazato, Toshiyuki Okazaki, Toshitaka Fujihara, Kohhei Nakajima, Hideo Mure, Kazuyuki Kuwayama, Tomoyo Hara and Shinji Nagahiro : Blocking of the interaction between Wnt proteins and their co-receptors contributes to the anti-tumor effects of adenovirus-mediated DKK3 in glioblastoma, Cancer Letters, Vol.356, 496-505, 2015. (Summary) The effect of the third member of the Dickkopf family (DKK3) in the Wnt pathway in glioblastoma remains unclear. We first demonstrated the non-specific interaction of Wnt3a and Wnt5a with the receptors LRP6 and ROR2 and the up-regulation of the Wnt pathway in glioblastoma cells. We used an adenovirus vector and found that an increase in DKK3 protein attenuated the expression of Wnt3a, Wnt5a and LRP6, but not of ROR2, and their interaction, thereby affecting both canonical- and non-canonical Wnt downstream cascades. This produced anti-tumor effects in GBM xenograft models. The suppression of Wnt pathways upstream by DKK3 may have promise for the treatment of glioblastoma. (Keyword) Adenoviridae / Animals / apoptosis / Blotting, Western / cell proliferation and differentiation / Flow Cytometry / Genetic Vectors / Glioblastoma / Humans / Immunoenzyme Techniques / Immunoprecipitation / Intercellular Signaling Peptides and Proteins / Low Density Lipoprotein Receptor-Related Protein-6 / male / Mice / Mice, Inbred BALB C / Mice, Nude / Proto-Oncogene Proteins / RNA, Messenger / Real-Time Polymerase Chain Reaction / Receptor Tyrosine Kinase-like Orphan Receptors / Reverse Transcriptase Polymerase Chain Reaction / Tumor Cells, Cultured / Wnt Proteins / Wnt3A Protein / Xenograft Model Antitumor Assays (Tokushima University Institutional Repository) ● Metadata: 106342 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.canlet.2014.09.045 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25301448 ● Summary page in Scopus @ Elsevier: 2-s2.0-84919491383 (Tokushima University Institutional Repository: 106342, DOI: 10.1016/j.canlet.2014.09.045, PubMed: 25301448, Elsevier: Scopus)
25.	Nobuaki Yamamoto, Junichiro Satomi, Yuka Terasawa, Sogabe Syu, Kohhei Nakajima, Yasuhito Sato, Bando Kazuhiko, Agawa Masahito, Asano Noboru, Hondo Hideki, Yuishin Izumi, Ryuji Kaji and Shinji Nagahiro : 脳梗塞発症後早期からの抗血小板薬使用が予後に及ぼす影響の検討, Japanese Journal of Stroke, Vol.36, No.6, 419-424, 2014. (Link to Publication Site) ● Publication site (DOI): 10.3995/jstroke.36.419 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282679616796928 ● Search Scopus @ Elsevier (DOI): 10.3995/jstroke.36.419 (DOI: 10.3995/jstroke.36.419, CiNii: 1390282679616796928)
26.	Teruyoshi Kageji, Hiroyoshi Watanabe, Yoshifumi Mizobuchi, Kohhei Nakajima and Shinji Nagahiro : 悪性胚細胞腫瘍に対する外科的治療の意義と化学治療の選択, 日本内分泌学会雑誌:第24回日本間脳下垂体腫瘍学会Proceeding, Vol.90, 62-64, 2014.
27.	Kohhei Nakajima, Yoichi Maekawa, Keiko Kataoka, Chieko Ishifune, Jun Nishida, Hideki Arimochi, Akiko Kitamura, Takayuki Yoshimoto, Shuhei Tomita, Shinji Nagahiro and Koji Yasutomo : The ARNT-STAT3 axis regulates the differentiation of intestinal intraepithelial TCRαβ⁺CD8αα⁺cells., Nature Communications, Vol.4, 2112, 2013. (Summary) Intestinal intraepithelial T cells contribute to the regulation of inflammatory responses in the intestine; however, the molecular basis for their development and maintenance is unknown. The aryl hydrocarbon receptor complexes with the aryl hydrocarbon receptor nuclear translocator (ARNT) and senses environmental factors, including gut microbiota. Here, we identify ARNT as a critical regulator of the differentiation of TCRαβ(+)CD8αα(+) intestinal intraepithelial T cells. Mice deficient in either ARNT or aryl hydrocarbon receptor show a greater than- eight-fold reduction in the number of TCRαβ(+)CD8αα(+) intestinal intraepithelial T cells. The number of TCRαβ(+)CD8αα(+) intestinal intraepithelial T cells is increased by treatment with an aryl hydrocarbon receptor agonist in germ-free mice and is decreased by antibiotic treatment. The Arnt-deficient precursors of TCRαβ(+)CD8αα(+) intestinal intraepithelial T cells express low amounts of STAT3 and fail to differentiate towards the TCRαβ(+)CD8αα(+) cell fate after IL-15 stimulation, a deficiency that is overcome by overexpression of Stat3. These data demonstrate that the ARNT-STAT3 axis is a critical regulator of TCRαβ(+)CD8αα(+) intestinal intraepithelial T-cell development and differentiation. (Keyword) Animals / Antigens, CD8 / Aryl Hydrocarbon Receptor Nuclear Translocator / CD8-Positive T-Lymphocytes / Cell Differentiation / Cells, Cultured / Female / Gene Expression Regulation / Interleukin-15 / Intestinal Mucosa / Intestines / Mice / Mice, Inbred C57BL / Mice, Transgenic / Precursor Cells, T-Lymphoid / Receptors, Antigen, T-Cell, alpha-beta / STAT3 Transcription Factor / Signal Transduction / beta-Naphthoflavone (Tokushima University Institutional Repository) ● Metadata: 105939 (Link to Publication Site) ● Publication site (DOI): 10.1038/ncomms3112 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23836150 ● Summary page in Scopus @ Elsevier: 2-s2.0-84880260699 (Tokushima University Institutional Repository: 105939, DOI: 10.1038/ncomms3112, PubMed: 23836150, Elsevier: Scopus)
28.	Shinji Nagahiro and Kohhei Nakajima : 輸血拒否患者の髄膜腫手術, Practical Currently, Vol.18, No.7, 820-827, 2008.

Academic Paper (Unrefereed Paper):

1.	Kohhei Nakajima, Nobuhisa Matsushita, Yoshifumi Mizobuchi, Takashi Abe, Teruyoshi Kageji and Shinji Nagahiro : 高齢者における頭蓋内多発性病変, Practical Currently, Vol.25, No.3, 268-272, 2015.

Proceeding of International Conference:

1.	Kenji Shono, Izumi Yamaguchi, Toshitaka Fujihara, Keiko Kitazato, Kohhei Nakajima, Yoshifumi Mizobuchi, Hideo Mure, Kohhei Nakajima, Junichiro Satomi, Shinji Nagahiro and Yasushi Takagi : Celecoxib inhibits proliferation and induces apoptosis in glioma stem cells and an animal model of glioblastoma., 22ND ANNUAL SCIENTIFIC MEETING AND EDUCATION DAY OF THE SOCIETY FOR NEURO-ONCOLOGY, San Francisco, Nov. 2017.
2.	Junichiro Satomi, Yasuhisa Kanematsu, Masaaki Korai, Yuki Yamamoto, Nobuaki Yamamoto, Yoshifumi Mizobuchi, Hideo Mure, Yoshiteru Tada, Kohhei Nakajima, Toshiyuki Okazaki and Toshitaka Fujihara : Acute stroke management using image sharing on smart phones and tablet devices, 14TH CONGRESS OF THE WORLD FEDERATION OF INTERVENTIONAL AND THERAPEUTIC NEURORADIOLOGY, Budapest, Oct. 2017.
3.	Junichiro Satomi, Yoshiteru Tada, Yasuhisa Kanematsu, Kazuyuki Kuwayama, Kenji Yagi, Tomoya Kinouchi, Kohhei Nakajima, Nobuhisa Matsushita, Takeshi Miyamoto, Tadashi Yamaguchi, Masaaki Korai, Hideo Mure, Keiko Kitazato and Shinji Nagahiro : A Pilot Study of the Mineralocorticoid Receptor Blocker Eplerenone in Hypertensive Patients with Unruptured Cerebral Aneurysms, International Stroke Conference 2016, Los Angeles, Feb. 2016.
4.	Kenji Shouno, Teruyoshi Kageji, Yoshifumi Mizobuchi, Toshitaka Fujihara, Keiko T Kitazato, Kohhei Nakajima, Hideo Mure, Kazuyuki Kuwayama and Shinji Nagahiro : Sonodynamic 5-ALA plus ultrasound therapy augments anti-tumor effects in the oncogene knock-in glioma stemcells, 20th Annual Socientific Meeting and Education Day of the Society for Neuro-Oncology, Nov. 2015.
5.	Toshitaka Fujihara, Teruyoshi Kageji, Yoshifumi Mizobuchi, Keijiro Hara, Kenji Shouno, Kohhei Nakajima, Hideo Mure, Kazuyuki Kuwayama and Shinji Nagahiro : Down-regulation of MDR1 by DKK3 attenuates chemoresistance to temozolomide, and potentiates its anti-tumor effects, 20th Annual Socientific Meeting and Education Day of the Society for Neuro-Oncology, Nov. 2015.
6.	Teruyoshi Kageji, Yoshifumi Mizobuchi, Kohhei Nakajima, Hiroyoshi Watanabe, Kazumi Okamura, Shoji Kagami and Shinji Nagahiro : Intensive chemotherapy followed by reduced radiation dose for intracranial non-germinomatous germ cell tumors, 20th Annual Socientific Meeting and Education Day of the Society for Neuro-Oncology, Nov. 2015.
7.	F Watanabe, N Inoue, K Okamura, Shinji Nagahiro, Yoshifumi Mizobuchi, Kohhei Nakajima, Teruyoshi Kageji and Shoji Kagami : Intensive Chemotherapy Followed by Reduced Dose Radiation for Intracranial Non-germinomatous Germ Cell, The 4th International CNS Germ Cell Tumor Symposium, Apr. 2015.
8.	Teruyoshi Kageji, Shoji Kagami, Kohhei Nakajima, Yoshifumi Mizobuchi and Shinji Nagahiro : Strategy and Clinical Results for Intracranial Non-germinomatous Germ Cell Tumors Induced Intensive, The 4th International CNS Germ Cell Tumor Symposium, Apr. 2015.
9.	Hiromichi Ito, Kenji Mori, Yoshihiro Touda, 藤原敏孝, Yoshiteru Tada, Kohhei Nakajima, Teruyoshi Kageji, 飯田幸治, Shinji Nagahiro, 高橋幸利 and Shoji Kagami : VNSにより発作頻度，認知行動面に改善が認められたAERRPSの1例, 第9回日本てんかん学会中国・四国地方会, Feb. 2015.
10.	Yoshifumi Mizobuchi, T Okazaki, Teruyoshi Kageji, Kazuyuki Kuwayama, KT Kitazato, Hideo Mure, Keijiro Hara, Ryoma Morigaki, Kazuhito Matsuzaki, Kohhei Nakajima, T Fujihara and Shinji Nagahiro : A combination of interferon-beta and temozolomide augments anti-tumor effects through p73/YAP-mediated apoptosis by PML in glioblastoma, The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 SNO Scientific Meeting and Education Day, San Francisco, Nov. 2013.
11.	Keijiro Hara, Teruyoshi Kageji, Yoshifumi Mizobuchi, T Okazaki, T Fujihara, Kohhei Nakajima, Hideo Mure, Kazuyuki Kuwayama, T Hara and Shinji Nagahiro : REIC/Dkk-3, one of Dickkopf(Dkk)family members, contributes to the anti-tumor effects in glioblastoma through regulation of both Wnt signal pathways, The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 SNO Scientific Meeting and Education Day, San Francisco, Nov. 2013.
12.	Kohhei Nakajima, Keijiro Hara, Teruyoshi Kageji, Yoshifumi Mizobuchi, KT KItazato, T Fujihara, Kazuyuki Kuwayama, R Otsuka, DK Kung and Shinji Nagahiro : Down-regulation of MDR by Ad-REIC contributes to augment the chemotherapy by temozolomide, The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 SNO Scientific Meeting and Education Day, San Francisco, Nov. 2013.
13.	Junichiro Satomi, Shinji Nagahiro, Shunji Matsubara, Masaaki Uno, Koichi Satoh, Norio Nakajima, Kohhei Nakajima, Kyoko Nishi and Ryoma Morigaki : Combined treatment for intracranial giant aneurysms, 9th International Conference on Cerebrovascular Surgery, Nagoya, Nov. 2009.

Proceeding of Domestic Conference:

1.	Mai Azumi, Kohhei Nakajima, Hiroki Ishibashi and Yasushi Takagi : Ideas for avoiding ventral complications in pediatric hydrocephalus surgery at our hospitalOne case where laparoscopy was effective and future efforts, 日本脳神経外科学会第83回学術総会, Oct. 2024.
2.	Toshitaka Fujihara, Yoshiteru Tada, Mai Azumi, Keijiro Hara, Kohhei Nakajima and Yasushi Takagi : Clinical characteristics and outcome of status epilepticus in patients with brain tumor, 日本脳神経外科学会第83回学術総会, Oct. 2024.
3.	Hiroshi Kagusa, Keijiro Hara, Kohhei Nakajima, 北里慶子, Yasuhisa Kanematsu and Yasushi Takagi : 外傷性脳内微小出血模倣モデルマウスにおける認知機能解析と認知症蛋白の蓄積の検討, 日本脳神経外科学会第83回学術総会, Oct. 2024.
4.	Kohhei Nakajima and Yasushi Takagi : 当院における膠芽腫の治療成績と治療継続に及ぼす因子の検討, 日本脳神経外科学会第83回学術総会, Oct. 2024.
5.	Keijiro Hara, Mai Azumi, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : 開頭摘出術を行った転移性脳腫瘍の術後成績, 日本脳神経外科学会第83回学術総会, Oct. 2024.
6.	Toshitaka Fujihara, Kohhei Nakajima, Mai Azumi, Keijiro Hara and Yasushi Takagi : Tips for temporal lobectomy for malignant brain tumor of temporal lobe, 第29回日本脳腫瘍の外科学会, Oct. 2024.
7.	Kohhei Nakajima and Yasushi Takagi : 当院における膠芽腫の治療成績と治療継続に及ぼす因子の検討, 第29回日本脳腫瘍の外科学会, Oct. 2024.
8.	砂田陽二郎, Mai Azumi, Kohhei Nakajima, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : 成人発症sellar Atypical Teratoid/Rhabdoid Tumorの一例, 第38回中国四国脳腫瘍研究会, Sep. 2024.
9.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Keijiro Hara, Mai Azumi and Yasushi Takagi : Epilepsy and perioperative seizures in surgical cases of supratentorial meningioma, 第57回日本てんかん学会学術集会, Sep. 2024.
10.	Mai Azumi, Kohhei Nakajima, Hiroki Ishibashi and Yasushi Takagi : Ideas for avoiding ventral complications in pediatric hydrocephalus surgery at our hospital - one case where laparoscopy was effective and future effort, 第52回日本小児神経外科学会, Jun. 2024.
11.	Toshitaka Fujihara, Kohhei Nakajima, Keijiro Hara, Mai Azumi, Taku Matsuda, Yoshiteru Tada and Yasushi Takagi : 脳腫瘍生検術におけるStealth Autoguideの初期使用経験, 日本脳神経外科学会第82回学術集会, Oct. 2023.
12.	Kohhei Nakajima, Mai Azumi, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : Sellar atypical teratoid/rhabdoid tumor の1例, 第28回日本脳腫瘍の外科学会, Sep. 2023.
13.	手島奈津美, Mai Azumi, Kohhei Nakajima, Tomohiro Matsuda, Izumi Yamaguchi, Toshitaka Fujihara, Shu Sogabe, Keijiro Hara and Yasushi Takagi : 術後管理に難渋した頭蓋咽頭腫の1例, 第95回日本脳神経外科学会中国四国支部学術集会, Apr. 2023.
14.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, 手島奈津美 and Yasushi Takagi : 深部電極留置におけるStealth Autoguideの初期使用経験:Posterior quadrantectomyを行った薬剤抵抗性てんかんの1例, 第17回日本てんかん学会中国・四国地方会, Feb. 2023.
15.	Yohjiroh Sunada, Takayoshi Shinya, Youichi Otomi, Youichi Otomi, Michiko Kubo, Hideki Otsuka, Masafumi Harada, Takashi Kawanaka, Yuishin Izumi, 安積麻衣, Kohhei Nakajima and Yasushi Takagi : F-18 FDG PET/CTにて多発性の神経根集積を認めた悪性リンパ腫の一例, 第137回日本医学放射線学会中国・四国地方会, Dec. 2022.
16.	Mai Azumi, Toshitaka Fujihara, Keijiro Hara, Kohhei Nakajima, Yoshifumi Mizobuchi and Yasushi Takagi : Examination about the predictors of outcome at discharge in postoperative brain tumor patients admitted to the intensive care units, 日本脳神経外科学会第81回学術総会, Sep. 2022.
17.	Mai Azumi, Kohhei Nakajima, 大野卓也, Aya Gohji, Tatsuo Mori, Kenji Mori and Yasushi Takagi : けいれん重積型急性脳症に類似した症状を呈し，West症候群に移行した乳児頭部外傷の1例, 第50回日本小児神経外科学会, Jun. 2022.
18.	Keijiro Hara, Yoshifumi Mizobuchi, Mai Azumi, Shu Sogabe, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : Hyper vascularityを呈した松果体部腫瘍の1例, 第93回日本脳神経外科学会中国四国支部学術集会, Apr. 2022.
19.	Toshitaka Fujihara, Yoshiteru Tada, Yoshifumi Mizobuchi, Kohhei Nakajima, Keijiro Hara, Mai Azumi and Yasushi Takagi : Epilepsy and perioperative seizure management in surgical cases of supratentorial meningioma, 日本脳神経外科学会第80回学術総会, Oct. 2021.
20.	Kohhei Nakajima, Yoshifumi Mizobuchi, Toshitaka Fujihara, Mai Azumi and Yasushi Takagi : 中枢神経原発悪性リンパ腫に対する大量メトトレキサート維持療法の意義, NMC Case Report Journal, Oct. 2021.
21.	Mai Azumi, Takeshi Miyamoto, Toshitaka Fujihara, Kohhei Nakajima, Keijiro Hara, Yoshifumi Mizobuchi and Yasushi Takagi : 特発性頭蓋内圧亢進様の症状のみで発症した小児脳腫瘍の1例, 第35回中国四国脳腫瘍研究会, Sep. 2021.
22.	Keijiro Hara, Yoshifumi Mizobuchi, Mai Azumi, Kohhei Nakajima and Yasushi Takagi : AIDS関連トキソプラズマ脳症の1例, 第91回(一社)日本脳神経外科学会中国四国支部学術集会, Apr. 2021.
23.	Toshitaka Fujihara, Yoshiteru Tada, Yoshifumi Mizobuchi, Kohhei Nakajima, Mai Azumi and Yasushi Takagi : 脳腫瘍手術における周術期抗てんかん薬使用と術後発作抑制効果についての検討, 第53回日本てんかん学会学術集会, Oct. 2019.
24.	Hiroshi Kagusa, Yoshifumi Mizobuchi, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : 眼窩内に転移した子宮頚癌の1例, 日本脳神経外科学会第78回学術集会, Oct. 2019.
25.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 当院における転移性脳腫瘍に対する術後放射線療法の検討, 日本脳神経外科学会第78回学術集会, Oct. 2019.
26.	Yoshiteru Tada, Toshitaka Fujihara, Kohhei Nakajima, Mai Azumi and Yasushi Takagi : 高齢発症てんかんの臨床的特徴, 日本脳神経外科学会第78回学術集会, Oct. 2019.
27.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Mai Azumi, Yoshiteru Tada and Yasushi Takagi : Perioperative prophylactic antiepileptic drug use and postoperative seizure in brain tumor surgery, Neurologia Medico-Chirurgica, Oct. 2019.
28.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 中枢神経原発性悪性リンパ腫に対する大量メトトレキサート維持療法の治療成績, 第36回日本脳腫瘍学会学術集会, Dec. 2018.
29.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 穿刺様頭痛で発見された中枢神経アスペルギルス症の1例, 第46回日本頭痛学会総会, Nov. 2018.
30.	Sumiko Yoshida, 原倫世, 山口佑樹, Takeshi Kondo, 遠藤ふうり, 筒井康継, 桝田志保, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, Kohhei Nakajima and Seiji Fukumoto : 急速に腫瘍が増大し悪性転化が疑われたCushing病の1例, 第28回臨床内分泌代謝Update, Nov. 2018.
31.	Tomoyo Hara, Sumiko Yoshida, 細井美希, 遠藤ふうり, 筒井康継, 桝田志保, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Kohhei Nakajima, Yoshimi Bando, Masahiro Abe and Seiji Fukumoto : 脳内，副鼻腔，下垂体に炎症を認めステロイドが著効した1例, 第22回日本臨床内分泌病理学会学術総会, Oct. 2018.
32.	Yoshiteru Tada, Toshitaka Fujihara, Kohhei Nakajima, Kenji Mori and Yasushi Takagi : 高齢発症てんかんの臨床的特徴，新規抗てんかん薬の効果, 日本脳神経外科学会第77回学術総会, Oct. 2018.
33.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Toshiyuki Okazaki, Hideo Mure and Yasushi Takagi : 膠芽腫におけるDKK3遺伝子導入による薬剤排泄ポンプの発現抑制の意義, 日本脳神経外科学会第77回学術総会, Oct. 2018.
34.	鹿草宏, Yoshifumi Mizobuchi, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : 慢性硬膜下血腫の手術方法の検討, 日本脳神経外科学会第77回学術総会, Oct. 2018.
35.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 当院における中枢神経原発悪性リンパ腫に対する大量メトトレキサート維持療法の治療成績, 日本脳神経外科学会第77回学術総会, Oct. 2018.
36.	Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Shinji Nagahiro and Yasushi Takagi : 顔面痙攣に対する手術手技 "shelter method" の有効性と長期予後, 日本脳神経外科学会第77回学術総会, Oct. 2018.
37.	Shoichi Hatada, 小山広士, Toshitaka Fujihara, Kohhei Nakajima, Yoshifumi Mizobuchi and Yasushi Takagi : 短期間で出血を繰り返した多発脳病変の1例, 第32回中国四国脳腫瘍研究会, Sep. 2018.
38.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, Masafumi Harada, Junichiro Satomi and Shinji Nagahiro : 非痙攣性てんかん重積診断におけるArterial Spin Labeling法の有用性, 第51回日本てんかん学会年次学術集会, Nov. 2017.
39.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, Masafumi Harada, Junichiro Satomi and Shinji Nagahiro : 当院で経験した非痙攣性てんかん重積症例の検討, 日本脳神経外科学会第76回学術総会, Oct. 2017.
40.	Kohhei Nakajima, 榎本紀哉, 安積麻衣, Shinya Ohkita, Yoshifumi Mizobuchi and Shinji Nagahiro : 脳脊髄液中に好酸球増多を認めたシャント機能不全の1例, 第45回日本小児神経外科学会, Jun. 2017.
41.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, 飯田幸治 and Shinji Nagahiro : 同側の未破裂中大脳動脈瘤を合併した左海馬硬化症による難治性内側側頭葉てんかんの一例, 第11回てんかん学会中国・四国地方会, Feb. 2017.
42.	Yoshiteru Tada, 藤原敏孝, Kohhei Nakajima, Yoshihiro Touda, Hiromichi Ito, Tatsuo Mori, 郷司彩, 飯田幸治, 森謙治 and Shinji Nagahiro : 徳島大学てんかんセンターの取り組みと課題, 全国てんかんセンター協議会総会 JEPICA 2017 in Nara, Feb. 2017.
43.	藤原敏孝, Kohhei Nakajima, Hideo Mure, 飯田幸治 and Shinji Nagahiro : 同側の未破裂中大脳動脈瘤を合併した左海馬硬化症による難治性内側側頭葉てんかんの一例, 第40回日本てんかん外科学会, Jan. 2017.
44.	藤原敏孝, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, Junichiro Satomi, Masafumi Harada and Shinji Nagahiro : Stroke Care Unitでのてんかん診断-Arterial Spin Labeling法の有用性, 第32回NPO法人日本脳神経血管内治療学会学術総会, Nov. 2016.
45.	藤原敏孝, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, Junichiro Satomi, Masafumi Harada and Shinji Nagahiro : Stroke Care Unitでのてんかん診断-Arterial Spin Labeling法の有用性, 第50回日本てんかん学会学術集会, Oct. 2016.
46.	Yoshiteru Tada, Nobuaki Yamamoto, 藤原敏孝, Kohhei Nakajima, 香川幸太, 片桐匡弥, 飯田幸治, Ryuji Kaji and Shinji Nagahiro : 自己免疫性介在性脳炎後の難治性てんかんの1例, 第50回日本てんかん学会学術集会, Oct. 2016.
47.	Kohhei Nakajima, Yoshifumi Mizobuchi and Shinji Nagahiro : 放射線治療を温存した中枢神経原発悪性リンパ腫の治療とその意義, 日本脳神経外科学会第75回学術総会, Sep. 2016.
48.	藤原敏孝, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, Junichiro Satomi, Masafumi Harada and Shinji Nagahiro : Stroke Care Unitでのてんかん診断-Arterial Spin Labeling法の有用性, 日本脳神経外科学会第75回学術総会, Sep. 2016.
49.	Yoshiteru Tada, Yasuhisa Kanematsu, Junichiro Satomi, Kazuyuki Kuwayama, Kenji Yagi, Tomoya Kinouchi, Kohhei Nakajima, Masaaki Korai, Hideo Mure, Takeshi Miyamoto, 山口真司, 北里慶子 and Shinji Nagahiro : 高血圧症合併未破裂脳動脈瘤に対するミネラルコンチコイド受容体阻害薬の有効性に関するパイロット試験, 日本脳神経外科学会第75回学術総会, Sep. 2016.
50.	Yoshifumi Mizobuchi, Kohhei Nakajima, Shinya Ohkita, 藤原敏孝 and Shinji Nagahiro : 悪性リンパ腫に対するリツキサンを併用し大量MTXメインテナンス療法, 第21回日本脳腫瘍の外科学会, Sep. 2016.
51.	鳥居裕太, 西尾進, 平田有紀奈, 天野里江, 山尾雅美, 高松直子, Kenya Kusunose, Kohhei Nakajima, Junichiro Satomi, Hirotsugu Yamada, Shinji Nagahiro and Masataka Sata : 若年女性の再発性脳梗塞の原因と考えられた頸動脈分岐部膜様構造物の1例, 第57回日本神経学会学術大会, May 2016.
52.	Yoshifumi Mizobuchi, Kohhei Nakajima, Teruyoshi Kageji and Shinji Nagahiro : 頭蓋咽頭腫に対する外科的治療を中心とした治療戦略, 第26回日本間脳下垂体腫瘍学会, Feb. 2016.
53.	Yoshiteru Tada, 藤原敏孝, Kohhei Nakajima, Teruyoshi Kageji, Yoshihiro Touda, Hiromichi Ito, Kenji Mori, 香川幸太, 飯田幸治 and Shinji Nagahiro : 発作時に過呼吸をきたす前頭葉てんかんの1例, 第49回日本てんかん学会学術集会, Oct. 2015.
54.	Kohhei Nakajima, Yoshifumi Mizobuchi, Teruyoshi Kageji, Kazumi Okamura, Hiroyoshi Watanabe and Shinji Nagahiro : 悪性胚細胞性腫瘍に対する化学療法を強化した集学的治療, 一般社団法人日本脳神経外科学会第74回学術総会, Oct. 2015.
55.	Yoshifumi Mizobuchi, Kohhei Nakajima, Teruyoshi Kageji and Shinji Nagahiro : 高齢者における髄膜腫手術の適応と問題点, 第20回日本脳腫瘍の外科学会, Sep. 2015.
56.	Yoshifumi Mizobuchi, 山口真司, Kohhei Nakajima, Teruyoshi Kageji and Yoshimi Bando : 術後長年経過して再発を繰り返した嚢胞性infiltrating astrocytomaの1例, 第33回日本脳腫瘍病理学会, May 2015.
57.	鹿草宏, Kohhei Nakajima, Yoshifumi Mizobuchi, Teruyoshi Kageji and Shinji Nagahiro : 眼窩内腫瘍の2例, 第79回日本脳神経外科学会中国四国支部学術集会, Apr. 2015.
58.	Hiromichi Ito, 東田好弘, Shoji Kagami, 森健司, 藤原敏孝, Yoshiteru Tada, Kohhei Nakajima, Teruyoshi Kageji, Shinji Nagahiro, 飯田幸治 and 高橋幸利 : VNSにより発作頻度，認知行動面に改善が認められたAERRPSの1例, 第9回日本てんかん学会中国・四国地方会, Feb. 2015.
59.	Yoshiteru Tada, 藤原敏孝, Kohhei Nakajima, Teruyoshi Kageji, Shinji Nagahiro, 東田好弘, Hiromichi Ito, 森健司, 香川幸太 and 飯田幸治 : 発作時に過換気をきたす前頭葉てんかんの1例, 第9回日本てんかん学会中国・四国地方会, Feb. 2015.
60.	Teruyoshi Kageji, Motohiro Hirasawa, Yoshifumi Mizobuchi, Kohhei Nakajima and Shinji Nagahiro : 小児後頭蓋窩腫瘍に対する後頭下開頭の整容的工夫, 第7回日本整容脳神経外科研究会, Apr. 2014.
61.	Kohhei Nakajima, Yoshifumi Mizobuchi, Teruyoshi Kageji and Shinji Nagahiro : レクセルシステムを用いた安全な定位的脳生検術, 第23回脳神経外科手術と機器学会, Apr. 2014.
62.	Teruyoshi Kageji, Shinji Nagahiro, Yoshifumi Mizobuchi and Kohhei Nakajima : 脳神経外科手術における術後出血の検討 -術後出血を防ぐための基本-, 第23回脳神経外科手術と機器学会, Apr. 2014.
63.	山口真司, Kohhei Nakajima, Yoshifumi Mizobuchi, Teruyoshi Kageji, Shinji Nagahiro, Hiromichi Ito and Kenji Mori : 進行性頭囲拡大を呈した乳児外傷性脳内出血の1例, 第77回(一社)日本脳神経外科学会中国四国支部学術集会, Apr. 2014.
64.	Nobuaki Yamamoto, Junichiro Satomi, Yuka Terasawa, Sogabe Syu, Kohhei Nakajima, Yasuhito Sato, Bando Kazuhiko, Agawa Masahito, Asano Noboru, Hondo Hideki, Yuishin Izumi, Ryuji Kaji and Shinji Nagahiro : 脳梗塞発症後早期からの抗血小板薬使用が予後に及ぼす影響の検討, 2014年脳卒中学会総会, Mar. 2014.
65.	Kohhei Nakajima, Yoshiteru Tada, Kazuyuki Kuwayama, Junichiro Satomi, Shinji Nagahiro and 山本伸昭 : 脳卒中発症時のエイコサペンタエン酸/アラキドン酸比の検討, 第39回日本脳卒中学会総会, Mar. 2014.
66.	Teruyoshi Kageji, Yoshifumi Mizobuchi, Kohhei Nakajima and Shinji Nagahiro : 悪性胚細胞腫瘍に対する外科的治療の意義, 第24回日本間脳下垂体腫瘍学会, Feb. 2014.
67.	藤原敏孝, Yoshiteru Tada, Kohhei Nakajima, 香川幸太, Teruyoshi Kageji, 飯田幸治 and Shinji Nagahiro : 側方性の診断に頭蓋内電極からの脳波記録が有用であった難治性内側側頭葉てんかんの1例, 第47回日本てんかん外科学会, Feb. 2014.
68.	Kohhei Nakajima, Yoshifumi Mizobuchi, Teruyoshi Kageji and Shinji Nagahiro : 当院における中枢神経系原発悪性リンパ腫の現状と問題点, 第39回徳島脳神経外科談話会, Dec. 2013.
69.	藤原敏孝, Kohhei Nakajima, Yoshiteru Tada, Teruyoshi Kageji and Shinji Nagahiro : 当院におけるてんかん外科治療の取り組み, 第39回徳島脳神経外科談話会, Dec. 2013.
70.	亘雄也, Kohhei Nakajima, Yoshifumi Mizobuchi, Teruyoshi Kageji, Shinji Nagahiro, Mika Sakaki, Shinsuke Katoh and Takanori Hirose : 脊髄上衣腫摘出手術から13年後に頭蓋内播種を示した1例, 第27回中国四国脳腫瘍研究会, Sep. 2013.
71.	Hideo Mure, Kohhei Nakajima, Motohiro Hirasawa, Shinji Nagahiro, 小泉英貴 and Ryuji Kaji : パーキンソン病に合併した腰痛に対する脊髄刺激療法の1例，, 第1回徳島脳神経疾患談話会, Mar. 2013.
72.	Kohhei Nakajima and Koji Yasutomo : Aryl hydrocarbon receptor nuclear translocator as a regulator of the differentiation of intestinal intraepithelial CD8 T cells., Proceedings of the Japanese Society for Immunology, Dec. 2012.
73.	Kohhei Nakajima and Koji Yasutomo : Arnt, 第11回四国免疫フォーラム, Jun. 2012.
74.	Junichiro Satomi, Ryoma Morigaki, Kohhei Nakajima, Kenji Yagi and Kyoko Nishi : 大型内頚動脈瘤に対するhigh flow bypass及び頭蓋内親動脈コイル塞栓併用療法の中長期成績, 第39回日本脳卒中の外科学会, Apr. 2010.
75.	Teruyoshi Kageji, Kohhei Nakajima, Yoshifumi Mizobuchi, Shinji Nagahiro, Shunji Matsubara and Kazuhito Matsuzaki : 輸血拒否患者の巨大髄膜腫手術, 第23回中国四国脳腫瘍研究会, Sep. 2009.
76.	Norio Nakajima, Kohhei Nakajima, Junichiro Satomi, Shunji Matsubara, Masaaki Uno, Shinji Nagahiro, 曽我部周 and Koichi Satoh : 巨大内頚動脈瘤に対するHigh flow bypassと術中コイル親動脈閉塞の併用手術, 第38回日本脳卒中の外科学会, Mar. 2009.
77.	Kohhei Nakajima, Norio Nakajima, Kyoko Nishi, Junichiro Satomi, Shunji Matsubara, Masaaki Uno and Shinji Nagahiro : 当院における内頚動脈-海綿静脈洞部巨大動脈瘤の治療方針, 第31回徳島脳神経外科懇談会, Dec. 2008.

Et cetera, Workshop:

1.	Mai Azumi, Kohhei Nakajima, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : リツシマブ併用大量療法が奏功した難治性中枢神経原発悪性リンパ腫の1例, 第37回中四国脳腫瘍研究会, Sep. 2023.
2.	Tatsuya Haboshi, Yoshiteru Tada, Toshitaka Fujihara, 亘雄也, Kohhei Nakajima and Yasushi Takagi : 前方脳梁離断術を施行した成人難治性てんかんの2例, 第43回徳島脳神経外科談話会, Dec. 2017.
3.	Yoshiteru Tada, 藤原敏孝, Kohhei Nakajima and Shinji Nagahiro : 慢性頭蓋内電極留置後に左選択的偏桃体海馬切除を行った症例, 第42回徳島脳神経外科談話会, Dec. 2016.
4.	安積麻衣, 藤原敏孝, Shinya Ohkita, Kohhei Nakajima, Yoshifumi Mizobuchi and Shinji Nagahiro : 治療に難渋した小児シャント感染の1例, 第42回徳島脳神経外科談話会, Dec. 2016.
5.	鹿草宏, Yoshifumi Mizobuchi, Kohhei Nakajima and Shinji Nagahiro : 進行性の聴力低下をきたした松果体嚢胞の1例, 第30回中国四国脳腫瘍研究会, Sep. 2016.
6.	山口泉, Junichiro Satomi, 曽我部周, 吉岡正太郎, Kohhei Nakajima, Tomoya Kinouchi, Yasuhisa Kanematsu, 山本雄輝, Nobuaki Yamamoto, Tetsuzo Wakatsuki and Shinji Nagahiro : OCTを用いて塞栓源を同定しえた一例, 第8回徳島Vascular Imaging研究会, Jul. 2016.
7.	岡田朝美, Yumiko Kotani, Shoji Kagami, 蔭山彩人, 松田拓 and Kohhei Nakajima : 成長曲線から疑うことが可能であった間脳下垂体腫瘍の2学童例, 第150回日本小児科学会徳島地方会, Jun. 2016.
8.	Shinya Ohkita, 藤原敏孝, Kohhei Nakajima, Yoshiteru Tada, Yoshifumi Mizobuchi and Shinji Nagahiro : Awake suegery ― 当院でのfirst case, 第3回徳島脳神経疾患談話会, Mar. 2016.
9.	Kohhei Nakajima, Yoshifumi Mizobuchi, Shinya Ohkita, 鹿草宏, 萩野寛隆 and Shinji Nagahiro : 錐体斜台部髄膜腫に対するCombined Pre-and Retrosiqmoid Approachの有用性, 第41回徳島脳神経外科談話会, Dec. 2015.
10.	藤原敏孝, Yoshiteru Tada, Kohhei Nakajima, Junichiro Satomi and Shinji Nagahiro : WADAテストの実際, 第41回徳島脳神経外科談話会, Dec. 2015.
11.	曽我部周, Junichiro Satomi, Kohhei Nakajima, 山口泉, Kazuyuki Kuwayama, 吉岡正太郎, Shinji Nagahiro, Nobuaki Yamamoto and Tetsuzo Wakatsuki : 光干渉断層法を用いて塞栓源を同定しえた脳梗塞の一例, 第24回NPO法人日本脳神経血管内治療学会中国四国地方会, Sep. 2015.
12.	松田拓, Yoshifumi Mizobuchi, Kohhei Nakajima, Teruyoshi Kageji, Shinji Nagahiro and Hiroyoshi Watanabe : 成人に発症した頭蓋内横紋筋肉腫の1例, 第29回中国四国脳腫瘍研究会, Sep. 2015.
13.	Kohhei Nakajima, 松田拓, Yoshifumi Mizobuchi, Teruyoshi Kageji and Shinji Nagahiro : 多房性病変を呈したRosette-forming glioneuronal tumorの1例, 第20回四国脳神経外科カンファレンス, Aug. 2015.
14.	Yoshiteru Tada, Toshitaka Fujihara, Kohhei Nakajima, Teruyoshi Kageji and Shinji Nagahiro : ビデオ脳波モニタリングの有用性, 第27回徳島てんかん談話会, Jul. 2015.
15.	曽我部周, Junichiro Satomi, Kohhei Nakajima, 山口泉, Kazuyuki Kuwayama, 吉岡正太郎, Shinji Nagahiro, Nobuaki Yamamoto and Tetsuzo Wakatsuki : OCTを用いて塞栓源を同定しえた脳梗塞の1例, 第17回徳島脳血管障害カンファレンス, May 2015.
16.	Kohhei Nakajima, Yoshifumi Mizobuchi, Teruyoshi Kageji and Shinji Nagahiro : 再発中枢神経原発悪性リンパ腫に対しリツキサンが有効であった2症例, 第19回四国脳神経外科カンファレンス, Aug. 2014.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Antitumor effect of Group-specific component derived Macrophage Activating Factor (GcMAF) on glioblastoma (Project/Area Number: 26861153 )
Anti-tumor effects and Regulation of Wnt signaling pathway of adenovirus-mediated DKK3 in glioblastoma (Project/Area Number: 25462264 )
Search by Researcher Number (40710554)

Associate Professor : Nakajima, Kohhei

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)